McDermott + Bull Partner Ken Dropiewski talks with Endeavour Vision Partner Rob Barmann about typical investment sizes in their portfolio companies.
Author: Ken Dropiewski
CARMAT Gets Blended Funding of up to €17.5m as a Winner of the European Innovation Council (EIC) Accelerator
Obtention of a €2.5m grant and potential equity investments of €15m PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that it has been […]
Acutus Medical Announces Full Market Release of next generation software platform AcQMap 8.5
Software improvements further leverage the system’s unique ultrasound capabilities for non-contact anatomy reconstruction CARLSBAD, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the full commercial release of AcQMap […]
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare […]
Shineco, Inc. Subsidiary Receives Prior Approval Supplement from the NMPA Jiangsu Bureau for the Marketing Approval of “Cardiac 5-Minute Test”
BEIJING, Dec. 19, 2022 (GLOBE NEWSWIRE) — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company’s controlled affiliate Changzhou Biowin Pharmaceutical Co., Ltd. (“CBP”) has received the Prior Approval Supplement from the Jiangsu […]
Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States
SINGAPORE, Dec. 16, 2022 /PRNewswire/ — Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays. The use of small peptides, conjugated with gold nanoparticles, allows a […]
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End Southlake, Texas, Dec. 16, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also […]
ELECTRODUCER ANNOUNCES THE PUBLICATION OF POSITIVE RESULTS FROM ITS PILOT STUDY IN EUROINTERVENTION MEDICAL JOURNAL
The first of its kind study involved 60 patients and confirmed Electroducer Sleeve® as a safe and effective treatment for heart diseases The company plans to launch its device in the US market by the end of 2023, followed by the European market in 2024 Grenoble, France, December 15, 2022 – Electroducer, […]
BioCardia Announces $3.6 Million Private Placement of Common Stock
SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with […]
Aziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings Corporation
Follows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million SILVER SPRING, Md., Dec. 15, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, […]
Recent
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
Popular
- No commented posts yet